BFM BOURSE – Onxeo : Vers la réparation de l’ADN des cellules tumorales
Read more on BFM Bourse (in French)
LES ECHOS – Onxeo veut contrer la réparation de l’ADN des cellules tumorales
Read the article in Les Echos (in French)
CANCER RESEARCH NEWS – A new cancer combination
Read the article in Cancer Research News
Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference
January 9-12, 2017 in San Francisco, CA In 2016, Onxeo has achieved a number of significant milestones, positioning the Company […]
Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC
Paris (France), Copenhagen (Denmark), – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of […]
Passing on Onxeo’s Extraordinary and Ordinary General Meeting
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment
Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial Paris […]
Onxeo First Quarter 2016 Financial Information and Business Update
Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext […]
Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Publication of Shareholder Letter
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]
Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update
Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients […]
Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors
Combination with checkpoint inhibitors decreased tumor growth rate and prolonged survival in syngeneic HCC mouse model Paris (France), Copenhagen (Denmark) – […]
Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Onxeo Strengthens AsiDNA™ Patent Protection in Europe
Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence […]
Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents
Following first positive results already obtained in several types of tumors New partnership with CIMA’s Immunology Program and the Liver […]
Onxeo announces closing of DNA Therapeutics acquisition
Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]
Onxeo Reports 2015 Full-Year Results and Provides Business Update
2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in […]
Publication of 2015 Reference Document
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Announces The Evolution And Reinforcement Of Its Board Of Directors
Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors […]
Onxeo Ordinary and Extraordinary General Meeting on April 6, 2016
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Onxeo Announces First Outcomes of Livatag® Preclinical Plan
Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale Demonstrates Enhanced […]
Onxeo to attend upcoming investor conferences and medical meetings
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan
Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment Acquisition expands […]
Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Onxeo Announces Establishment of U.S. Subsidiary
Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S subsidiary Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]
Onxeo announces development of Beleodaq® oral formulation opening new opportunities for its HDAC inhibitor
The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq® Paris […]
Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA
Near- and mid term expected milestones Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the […]
Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031
Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair […]
Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology […]
Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America
Agreement covering seven South American countries Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a […]
Onxeo Reports First-Half 2016 Business Update and Consolidated Financials
– Expansion of orphan oncology pipeline through acquisition of DNA Therapeutics and lead compound AsiDNATM – Important development milestones on existing […]
Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]
Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative […]
Onxeo Launches Capital Increase
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in […]
Onxeo Raises €12.5 Million through Capital Increase with US and European Investors
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in […]
Onxeo Announces Its Financial Calendar for 2017
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology
Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class […]
Onxeo to Attend Two French Investor Conferences in January
Oddo Investor Forum, January 5-6, 2017 in Lyon Invest Securities BioMed Event, January 26, 2017 in Paris Paris (France), Copenhagen […]